Higgins DA et al. |
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. |
1996 |
Vaccine |
pmid:8782343
|
Cataldo DM and Van Nest G |
The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. |
1997 |
Vaccine |
pmid:9364672
|
Singh M et al. |
A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. |
1998 |
Vaccine |
pmid:9795387
|
Barchfeld GL et al. |
The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. |
1999 |
Vaccine |
pmid:10067675
|
Minutello M et al. |
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. |
1999 |
Vaccine |
pmid:9987141
|
Hilgers LA et al. |
Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. |
1999 |
Vaccine |
pmid:9987157
|
Podda A |
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. |
2001 |
Vaccine |
pmid:11257408
|
Greer CE et al. |
The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. |
2000 |
Vaccine |
pmid:11137233
|
Skeiky YA et al. |
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. |
2002 |
Vaccine |
pmid:12213399
|
Stephenson I et al. |
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. |
2003 |
Vaccine |
pmid:12639491
|
Romera SA et al. |
Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle. |
2000 |
Vaccine |
pmid:10924795
|
Boyce TG et al. |
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. |
2000 |
Vaccine |
pmid:10930676
|
Süli J et al. |
Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. |
2004 |
Vaccine |
pmid:15308373
|
BenÃsek Z et al. |
Experimental squalene adjuvant. II. Harmlessness and local reactogenity. |
2004 |
Vaccine |
pmid:15308374
|
Madhun AS et al. |
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. |
2010 |
Vaccine |
pmid:21034828
|
Cristiani C et al. |
Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. |
2011 |
Vaccine |
pmid:21396903
|
Garcia-Sicilia J et al. |
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. |
2011 |
Vaccine |
pmid:21504774
|
Morel S et al. |
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. |
2011 |
Vaccine |
pmid:21256188
|
Esposito S et al. |
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. |
2011 |
Vaccine |
pmid:21199699
|
Esposito S et al. |
Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. |
2010 |
Vaccine |
pmid:20888873
|
Tritto E et al. |
Mechanism of action of licensed vaccine adjuvants. |
2009 |
Vaccine |
pmid:19200813
|
Ansaldi F et al. |
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. |
2009 |
Vaccine |
pmid:19200846
|
Camilloni B et al. |
Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. |
2009 |
Vaccine |
pmid:19410623
|
Phillips CJ et al. |
Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. |
2009 |
Vaccine |
pmid:19379786
|
Carmona A et al. |
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. |
2010 |
Vaccine |
pmid:20600478
|
Frey SE et al. |
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. |
2010 |
Vaccine |
pmid:20619382
|
Fabbiani M et al. |
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. |
2011 |
Vaccine |
pmid:21349364
|
Dell'Era L et al. |
Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. |
2012 |
Vaccine |
pmid:22138210
|
Okike IO et al. |
The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. |
2011 |
Vaccine |
pmid:21742005
|
Puig-Barberà J et al. |
Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. |
2007 |
Vaccine |
pmid:17889411
|
Guillon C et al. |
Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. |
2007 |
Vaccine |
pmid:17904700
|
Baldo V et al. |
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. |
2007 |
Vaccine |
pmid:17383057
|
Bråve A et al. |
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. |
2007 |
Vaccine |
pmid:17707956
|
Ansaldi F et al. |
Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. |
2008 |
Vaccine |
pmid:18294741
|
de Roux A et al. |
Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. |
2006 |
Vaccine |
pmid:16288937
|
O'Hagan DT et al. |
Cationic microparticles are a potent delivery system for a HCV DNA vaccine. |
2004 |
Vaccine |
pmid:15542189
|
Faenzi E et al. |
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. |
2012 |
Vaccine |
pmid:22521851
|
Hatz C et al. |
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. |
2012 |
Vaccine |
pmid:22626675
|
Candela S et al. |
An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. |
2013 |
Vaccine |
pmid:22766247
|
Langley JM et al. |
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. |
2012 |
Vaccine |
pmid:22469860
|
Dey AK et al. |
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. |
2012 |
Vaccine |
pmid:22366638
|
Reynales H et al. |
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. |
2012 |
Vaccine |
pmid:22902681
|
Ventura R et al. |
Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. |
2013 |
Vaccine |
pmid:22884665
|
Moro ML et al. |
A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. |
2013 |
Vaccine |
pmid:22885015
|
Chandramouli S et al. |
Generation of a parvovirus B19 vaccine candidate. |
2013 |
Vaccine |
pmid:23827313
|
Yang WH et al. |
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. |
2013 |
Vaccine |
pmid:23856331
|
Calabro S et al. |
The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. |
2013 |
Vaccine |
pmid:23684834
|
Segura-Velázquez R et al. |
Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant. |
2013 |
Vaccine |
pmid:23746458
|
Puig-Barberà J et al. |
MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. |
2013 |
Vaccine |
pmid:23731629
|
Rouleau I et al. |
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. |
2013 |
Vaccine |
pmid:24144473
|